Brief: UroGen Pharma Q2 Loss Per Share $1.44

UroGen Pharma

10/08/2020 13:45

Aug 10 (Reuters) - Urogen Pharma Ltd  UR8.F :
    * UROGEN PHARMA REPORTS SECOND QUARTER 2020 FINANCIAL
RESULTS AND
RECENT CORPORATE DEVELOPMENTS
    * Q2 LOSS PER SHARE $1.44
    * ON TRACK TO INITIATE A PIVOTAL UGN-102 PHASE 3 TRIAL BY
YEAR END
    * NOW EXPECTS 2020 TOTAL OPERATING EXPENSES IN RANGE OF $143
TO
$153 MILLION

Source text for Eikon:  ID:nBw9Bt5gTa 
Further company coverage:  UR8.F 

 ((Reuters.Briefs@thomsonreuters.com;))